AbbVie holds a strong portfolio of marketed and pipeline drugs. While the increasing competition to the company's key drug Humira should slow the growth for the company in the near term, we believe ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from ...

After spinning off from Abbott Labs in 2013, biopharmaceutical giant AbbVie had to establish its own culture. Here's how the ...

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with ...

The global diabetic nephropathy market revenue was around US$ 2.0 billion in 2022 and is estimated to reach US$ 3.3 billion by 2031, growing at a compound annual growth rate (CAGR) of 6% during the ...

Abbott rolled out its first over-the-counter glucose sensor in the U.S. on Thursday, just over one week after Dexcom began selling its competing product. The device, called Lingo, is intended to be ...

Axial Spondyloarthritis (axSpA) is a form of arthritis that mainly causes discomfort and inflammation in the spine and ...

Pat was united in marriage on October 1, 1977 to his high school sweetheart, Mickie Lee (nee Fisher). He worked 27 years at Abbott/Abbvie and retired in 2018. He was an avid and experienced diver and ...

AbbVie has succeeded in winning tentative approval to buy the Irish drug maker Shire, and Mylan Laboratories said it would acquire the international generic drug business from Abbott Laboratories.

Even more alarming is AbbVie's payout ratio of 216.7%, far surpassing the peer average of 141%. This sky-high figure means ...

Jade Abbott, 34, is working to ensure that African languages also benefit from generative AI. She aims to create data sets and natural language processing tools for these languages, which have ...